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Abstract
Due to the large interdependence between the molecular components of living systems, many phenomena, including those
related to pathologies, cannot be explained in terms of a single gene or a small number of genes. Molecular networks,
representing different types of relationships between molecular entities, embody these large sets of interdependences in a
framework that allow their mining from a systemic point of view to obtain information. These networks, often generated
from high-throughput omics datasets, are used to study the complex phenomena of human pathologies from a systemic
point of view. Complementing the reductionist approach of molecular biology, based on the detailed study of a small
number of genes, systemic approaches to human diseases consider that these are better reflected in large and intricate
networks of relationships between genes. These networks, and not the single genes, provide both better markers for
diagnosing diseases and targets for treating them. Network approaches are being used to gain insight into the molecular
basis of complex diseases and interpret the large datasets associated with them, such as genomic variants. Network
formalism is also suitable for integrating large, heterogeneous and multilevel datasets associated with diseases from the
molecular level to organismal and epidemiological scales. Many of these approaches are available to nonexpert users
through standard software packages.
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Introduction
The reductionist approach of molecular biology was very suc-
cessful in biomedicine. Getting insight into the molecular mech-
anisms underlying pathological processes allowed to use
molecular entities (e.g. genes, proteins and metabolites) as
markers for diagnosing diseases or targets for treating them.
Nevertheless, biological systems are the prototype of “complex
systems,” as they are characterized by a large number of molec-
ular components immersed in intricate networks of interac-
tions. As such, many of their properties resist a reductionist
approach and can only be tackled from a systemic point of
view [1–5].
Disease-related phenomena are not an exception, and the
reductionist approach has clear limitations in the case of com-
plex diseases involving a large number of “causative” or associ-
ated genes, such as cancer or Alzheimer’s disease [6]. The
reductionist approach to diseases assume that they can be
tracked back to a reduced number of molecular entities, whose
effects on the pathology are fundamentally additive, so that
studying them in isolation and later combining the results in a
simple way would allow for understanding the disease at mo-
lecular level. Even in prototypical monogenic diseases, for
which the reductionist approach is expected to work well, the
causative gene(s) do not work in isolation but are immersed in
large molecular networks. Consequently, even if the onset of a
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disease depends on a single gene, other important factors, such
as its severity or patient-specific manifestation, depend on
many other genes/mutations, requiring a more systemic ap-
proach for understanding them (e.g. cystic fibrosis [7]). The par-
tial failure of promising therapeutic approaches such as peptide
vaccines, genetic therapy, antisense RNA or rational design of
vaccines is partially attributed by some authors to their extreme
reductionist basis [4, 8–10]. The limitations of reductionist
approaches to diseases could also partially explain the continu-
ous reduction of new drugs brought to the marked in spite of in-
creased inversion [11], as the current model of drug-
development has a strong reductionist basis.
Systemic approaches to biological phenomena focus on the
complex networks of interactions between molecular compo-
nents instead of the detailed properties of components them-
selves [1–5]. These approaches were delayed in part by the lack
of large data required to build these networks. These datasets
are now generated by omics approach, and the networks as-
sembled from them are the prototypical subject of study of mo-
lecular systems biology [12–16]. These systemic approaches are
applied to the study of human pathologies, what is sometimes
called Network or Systems Medicine. The new evidence and
results derived from the application of systems medicine are
driving a paradigm shift in both the identification of new thera-
peutic targets and the development of drugs, leading to the
emergence of new disciplines such as network pharmacology
[17] and polypharmacology [18, 19].
In this review, we try to provide an introductory overview of
this emerging field. Since this is a hot topic and the field is fast-
moving, it is difficult to assemble a comprehensive summary
that fully covers the subject. Consequently, we focus on the
concepts that are well-established and form the basis of these
methodologies. We start by providing an overview on the main
molecular networks, focusing on their main organizing princi-
ples and their relationship with pathologies. Then we summa-
rize the main approaches for extracting disease-related
information from these networks. We pay special attention to
the practical application of these approaches, including infor-
mation for interested users on how to use these approaches
through standard software packages.
Molecular networks
A network (or graph in mathematical terms) is a representation
of a set of relationships between entities. Any phenomenon
that can be described in terms of entities linked by relationships
can be modeled as a graph. The entities are usually called nodes
or vertices, and the relationships are edges, links or connections
(Fig. 1). A node can represent a definite physical object (e.g. pro-
tein, metabolite, person, computer, etc.) or concepts that are
more complex (e.g. cell type, developmental stage, disease, soft-
ware subroutine, etc.). Likewise, edges can represent any type of
linkage between nodes (physical interaction between proteins,
chemical transformation between metabolites, hypertext link
between two web pages, subroutine call in a computer program,
etc.). Consequently, nodes and edges represent entities and
relationships understood in the broadest sense. The relation-
ship represented by the edges can be either directed, e.g. a
chemical transformation of a compound into another, or undi-
rected, e.g. a physical interaction between two proteins.
Similarly, the edges can have different associated values
(weights), representing a quantitative property, or all edges can
have the same value. Consequently, according to the nature of
their edges, networks can be classified as directed/undirected
and weighted/unweighted (Fig. 1). Some networks are not ho-
mogeneous in terms of the entities represented by their nodes
and edges. If the nodes (or edges) represent different types of
entities, the network is multipartite (Fig. 1). All these character-
istics (weights, direction, different types of nodes, etc.) depend
on the nature of the phenomenon we are modeling as a
network.
Once we have a given phenomenon/dataset represented as a
network, we can mine it using the tools of Graph Theory. These
approaches quantify topological network parameters that can
have a translation into properties of the phenomenon modeled
in that network, hence providing information on it.
Phenomena involving large datasets with intricate relation-
ship patterns are particularly suitable for network representa-
tion. Consequently, different datasets across diverse disciplines
have been modeled as networks. Network approaches are very
popular for analyzing “social networks,” where the nodes repre-
sent persons and the edges represent some type of social link-
age, such as friendship. Technological networks such as the
World Wide Web are also frequently subjected to this kind of
representation.
In Biology, this approach has been commonly used for repre-
senting ecological relationships, such as predator–prey linkages
(“food webs”), as there are enough data associated with them.
Molecular networks (i.e. those representing relationships be-
tween molecular entities or any other phenomena at molecular
level) are more recent, as the large datasets required to assem-
ble them are recent too. These datasets usually come from
“omics” techniques that allow retrieving large amounts of mo-
lecular information in a massive way, part of which can be rep-
resented as networks [13, 20].
The main molecular network is the “interactome,” in which
the nodes represent proteins and the (undirected) edges repre-
sent interactions between them [21]. The advent of high-
throughput experimental methods for detecting protein interac-
tions, in combination with methods for predicting interactions
and relationships from genomic information or for mining the
literature in search of described relationships, has made it pos-
sible to assemble large interactomes for most model organisms.
In many cases, these diverse “evidences” of interaction are com-
bined in different ways to obtain an interactome with high reli-
ability and coverage [22]). Especially for human protein
interactions, it is a common practice to use gene expression
data to instantiate a generic interactome obtained by cell-free,
high-throughput methods into that taking place at a particular
tissue or cell type [23].
Figure 2 shows the human interactome stored in the BIND
database [24].
Another molecular phenomenon usually represented as a
network is cellular metabolism. In a typical representation of a
metabolic network, the nodes are chemical compounds (metab-
olites) and the (directed) edges represent chemical transforma-
tions from one metabolite to another [26]. These metabolic
networks have been assembled mainly with the data accumu-
lated throughout decades of detailed experimental characteri-
zation of biochemical reactions as well as by homology-based
metabolic reconstruction. Sometimes, the metabolism is also
represented as a bipartite network with two types of nodes,
metabolites and enzymes. In this representation, the directed
edges represent enzyme-product (enzyme ! metabolite) and
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enzyme-substrate (metabolite ! enzyme) relationships. An
enzyme-centric representation in which nodes are enzymes
and edges represent “consecutive” enzymes (i.e. the product of
one enzyme is substrate for the other) is also used widely.
The “Regulome” is a network representation of the gene reg-
ulatory relationships taking place in a given organism. In this
network, nodes represent genes and the directed edges repre-
sent relationships between transcription factors and their regu-
lated genes [27]. Besides direction, edges in a regulome should
also contain information on whether the transcriptional control
is for activation or repression. This can be done either using
weighted edges (e.g. 1 for activation and –1 for repression) or
through a bipartite network with two types of edges, represent-
ing activation and repression relationships.
While these are the three major molecular networks, many
others have been assembled and studied. For example, “genetic
networks” are undirected networks representing genetic associ-
ations between genes: genes for which the phenotypic effects of
their mutation are not independent [28, 29]. The
“phosphorylome” is the (directed) network of associations be-
tween kinases and their protein substrates [30, 31]. Co-
expression networks are undirected networks where nodes are
proteins and edges link pairs of proteins with similar expression
patterns across a set of experiments [32].
The tendency is to combine many of these networks in mul-
tipartite networks [33]. For example, metabolic, gene regulation
and protein interaction data can be combined and represented
as a multipartite network with two types of nodes (metabolites
Figure 1: Left: Schematic representation of a small network with seven nodes and eight edges. Middle, a similar network with edge weights and directionality (di-
rected/weighted network). Right: A multipartite network with two different kinds of nodes (yellow circles and green boxes) and two types of edges (black and red).
Figure 2: Undirected and unweighted network representing the human protein–protein interactions stored in the BIND database [24]. Representation is generated with
Cytoscape [25]. The network comprises 19 905 nodes (proteins, green) and 38 706 edges (interactions, gray).
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and proteins) and three types of linkages: directed reactions be-
tween metabolites, undirected interactions between proteins,
and directed regulatory relationships between proteins.
Network approaches to diseases
Network medicine can be defined as systemic approaches to
study and treat human diseases. These approaches comple-
ment the classic reductionist approach of molecular biology
based on trying to understand a disease as caused by a problem
in one or a very small number of genes that can therefore be
treated by a single drug (“1 disease–1 gene–1 drug” paradigm).
Systemic approaches use a more holistic approach based on the
idea that diseases are better reflected at higher levels of com-
plexity involving many molecular entities as well as environ-
mental factors entangled in complex relationships. Network
approaches to diseases use networks to represent such complex
and large sets of molecular entities and their diverse relation-
ships, and graph theoretical and related methods to extract
disease-related information from these [16, 34–38]. While in the
reductionist approach individual genes and/or proteins are
markers and eventual therapeutic targets for diseases, in the
systemic/network approach, markers and targets are large
(sub)networks. The idea is that most diseases are better
reflected at the level of complex networks instead of single
genes. Accordingly, diseases arise as emergent properties of
complex networks, which are affected by both genetic and envi-
ronmental factors [39]. Diseases are seen as perturbations in the
network structure (e.g. rewiring) more than in the nodes (genes)
themselves [16].
In principle, all the molecular networks described in the pre-
vious section, representing different types of linkages between
diverse molecular entities, as well as multipartite networks that
combine them, can be used in these systemic approaches to
study diseases. The different capacity of these diverse molecu-
lar networks for assisting in the discovery of disease genes has
been benchmarked in some cases [40].
Disease-related genes and network
modules
The most obvious way in which network information can be
used to obtain disease-related information is to look into pro-
tein networks for topological features of the nodes associated
with disease. The degree of a node (number of connections) is a
very simple topological parameter, and in protein networks it
has been shown to be related to the “importance” of the corre-
sponding gene/protein for the organism. For example, highly
connected nodes (sometimes called “hubs”) tend to correspond
to essential genes [41] and to be conserved evolutionarily [42].
Another topological parameter related to node importance is
“betweenness.” The betweenness of a node is the number of in-
ternode shortest pathways that requires that particular node.
Nodes with high betweenness (sometimes called “bottlenecks”)
also tend to be essential genes, especially in directed networks
such as the regulome [43]. So, both hubs and bottlenecks would
be good candidates for disease-related proteins due to their im-
portance for the functioning of an organism. Indeed, it has been
shown that proteins involved in diseases tend to have more
interactors than average [34, 44–46] and higher betweenness
[45]. Nevertheless, even if more connected than the average,
disease-related proteins are not the hubs of interactomes [47].
The reason is that hubs are essential and hence their failure
would not lead to a viable organism that can manifest disease.
Moreover, these topological properties of disease-associated
genes are dependent on the characteristics of the disease
(Mendelian, somatic, monogenic, dominant/recessive, etc.) [48].
A key concept in network medicine is that of “disease-re-
lated module.” A module (also known as “cluster” or
“community”) is a group of nodes highly connected among
themselves but sparsely connected with the rest of the network
(Fig. 3). As such, “module” is a purely topological concept. In
molecular networks, these modules have been shown to com-
prise functionally related molecules [49]. For example, a set of
interacting proteins involved in the same biological process
and/or forming a macromolecular complex such as the ribo-
some or the proteasome forms a topological cluster in the
Figure 3: Relationships between topological, functional and disease-related modules. The schematic network has three topological modules. The proteins involved in
a specific function (“X”) are colored red. Those associated with a given disease (e.g. those whose mutation is known to cause “disease Y”) are highlighted with green
halos. Proteins known to be involved in “function X” tend to cluster in the network. Those associated with disease Y also tend to cluster in the same topological mod-
ule, indicating that disease Y may be related to a dysfunction of the biological process X. Mutations of other proteins in the same topological/functional module would
probably cause the disease as they disrupt the same process, but they have not yet been detected.
4 | Chagoyen et al.
interactome. Similarly, topological clusters detected in meta-
bolic networks are in good agreement with the traditional
metabolic pathways defined by expert knowledge and group-
ing-related metabolites [50]. Hence, topological modules within
molecular networks are also functional modules (Fig. 3) in the
sense that a given topological module can be associated with a
given biological function. This allows, e.g. to infer the function
of nodes using the principle of “guilt by association” [51, 52], i.e.
a node of unknown function immersed in a module/cluster
would probably share a role with the rest of the module. As
genes with similar functions cluster in molecular networks, so
do genes associated to the same disease (Fig. 3). This has been
shown in multiple global studies as well as in those focused in
particular diseases [53–56]. In a disease such as cancer, charac-
terized by the progressive accumulation of mutations that at
some point triggers the manifestation of pathology and other
phenotypic transitions, it has been shown that it is the cluster-
ing of these mutations in defined network modules which is as-
sociated with these transitions, and not the mere accumulation
of mutations all through the network [54]. Even in very complex
diseases involving hundreds/thousands of genes, these are not
spread through the network but tend to concentrate in a re-
duced number of modules/pathways (e.g. autism [57]). Not only
the genes associated with a given disease cluster in molecular
networks but those associated to a given symptom or patho-
phenotype (e.g. fever, hemorrhage, inflammation, seizures, etc.)
concentrate in networks as well [58]. Consequently, we can de-
fine a “disease module” as a topological network module associ-
ated with a disease, i.e. a network module that contributes to an
abnormal phenotype associated with that disease when its
components (nodes) are dysfunctional [35].
Locating disease-related modules
Disease-related modules are usually identified from an initial
set of “seed” genes associated with a given disease. These can
be genes whose mutation is known to cause the disease, genes
accumulating variants in observational studies such as
“genome-wide association studies” (GWAS), or genes/proteins
“altered” in some way during the manifestation of the disease
(e.g. differentially expressed).
The approaches for locating the topological module(s) asso-
ciated with an initial set of genes are generally called “network
diffusion” or “network propagation” [59, 60] (Fig. 4). These
approaches locate network modules(s) “enriched” in the initial
set of genes, generally by “propagating” some signal through
the network edges from this initial set of nodes and recording
the nodes at which the signal ends (Fig. 4). This can be done fol-
lowing different strategies. One possibility is to simulate
“random walkers” that move in the network following the edges
[61]. Algorithms developed to score the importance of web
pages based on the network of hypertext links connecting
them, such as Google’s PageRank, have been adapted to biologi-
cal networks [62]. Different forms of graph kernels have also
been used for this purpose [63], showing significant efficiency in
measuring distances and functional relationships in genetic
and protein networks [64, 65]. Physics-based approaches are
also popular. These treat network connections (edges) as metal
wires and simulate electric currents originated by applying volt-
age to sets of nodes, or diffuse heat starting from them. For ex-
ample, HotNet [66] treats seed nodes as heat sources and
network edges as “metal wires” able to transmit it. After simu-
lating this heat diffusion for a while, the final set of “hot” nodes
is reported as the resultant module. It is easy to see that heat
Figure 4: General strategy for discovering disease-related network modules. The starting point is an initial set of genes (a, b, c, e, i and m; red) related to the disease by
multiple types of evidence: phenotypic evidence, such as differential expression (top left), or genotypic evidence, such as variants found in GWAS (top right). These
genes are mapped to a biological network with three modules (1, 2 and 3; bottom left). A network propagation method detects module “1” as that related to the disease
(i.e. enriched in the initial set of genes). Consequently, genes f and d are potentially linked to the disease, since they are involved in this module, while genes i and m
could be discarded or ranked down in the prioritized list of variants.
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would tend to confine to the topological module with most of
initial nodes. Many of these approaches can be easily adapted
to weighted and/or directed networks: e.g. by allowing a larger
amount of signals to propagate through a “wider” edge, or by
forcing random walker to move obeying the directions of edges.
Similarly, they can be adjusted to work with multipartite and
heterogeneous networks with different types of entities and
relationships [49].
In some contexts, the modules detected from sets of mu-
tated genes or those accumulating GWAS variants are called
“genotypic modules,” as they come from genotypic evidences,
whereas those detected from sets of genes with altered expres-
sion are termed as “phenotypic modules” [67]. If both sources of
evidences are available for the same disease, they could map to
different modules, one related to the genetic regulation of the
processes/pathways associated to the disease, and another
reflecting the altered pathways themselves. Under the assump-
tion that both modules should be connected in some way, since
genotypic alterations determine the observed phenotypic ones,
some network propagation approaches use both genotypic and
phenotypic sets of genes and “expand” them by including the
genes required for connecting them [67].
Software for locating disease-related modules
A variety of free software is available to interested users for per-
forming “network propagation” with their datasets. These soft-
ware are available in different models, from command-line
tools to web interfaces, API services, etc. See Cowen et al. [60] for
a detailed list of available programs.
Of special interest for nonexpert users is the possibility of
using these approaches within Cytoscape (www.cytoscape.org),
a widely used package for visualizing and manipulating biologi-
cal networks [25]. This functionality is now integrated in the re-
cent versions of Cytoscape (3.6 and above), and can be imported
as plug-ins in previous versions [68]. This Cytoscape feature
includes implementations of two of the network propagation
approaches mentioned above: random walks and heat diffu-
sion. To use this feature, the user must first select the initial set
of nodes in Cytoscape, either in the network representation, via
the table panel, using the “Select” tab/menu, or by any other se-
lection mechanism. Then the user must go to the “Tools” menu
and select “Diffuse.” After performing network propagation, two
new attributes (data columns) are added to the nodes contain-
ing the scores produced by the two approaches. It is then possi-
ble to use other Cytoscape’s functionalities with these new
attributes, e.g. selecting the nodes with the highest values (as
potential detected modules) or coloring the nodes according to
their scores. Additionally, a new “Results Panel” tab shows up
with slider bars for automatically selecting top nodes according
to both scores.
Figure 5 shows an example of network propagation per-
formed with Cytoscape.
Utility of disease-related modules
The overlap between topological modules, functional modules
and disease-related modules, although not always perfect
(Fig. 3), allows working under the scenario that “disease X is
characterized by a malfunction/problem with biological path-
way/function Y, associated with the network topological mod-
ule Z.” This has multiple advantages with respect to using the
initial sets of genes without considering their network context.
The detected module allows the identification of new genes
potentially important/useful for the disease (e.g. “f” in Fig. 4,
connecting “a” and “e”). These could be genes not originally
identified due to experimental errors (“false negatives”) or sim-
ply genes not mutated or phenotypically altered but neverthe-
less important for understanding the disease and/or better
markers or targets for treating it. For example, Ruffalo et al. [69]
used network propagation to find genes previously known to be
associated with cancer that nonetheless neither present muta-
tions nor have altered expression.
On the other hand, this strategy allows us to discard genes
(e.g. “i” in Fig. 4). This has implications for “variant prior-
itization” [70]: GWAS-like studies usually report many variants
that have to be filtered/ranked. Network propagation
approaches are routinely used for this [71]. Something similar
happens with “copy number variation” (CNV) data associated
with a disease: these genomic rearrangements involve large ge-
nomic regions, and not all the genes within these regions are
necessarily causative. The pathological symptoms of CNVs vary
depending on the genetic background, such as dosage-sensitive
genes and recessive alleles located in the affected genomic re-
gion in each patient [72], making it challenging to discriminate
between benign and pathogenic CNVs [73]. Within the many
genes coded in a set of CNVs associated with a disease, those re-
lated to the disease are expected to cluster together in molecu-
lar networks, while the rest should be spread throughout the
whole network. These “unrelated” genes could also be due to
experimental errors (i.e. “false positives”).
Consequently, the final set of genes (refined by network
criteria as explained above) could be a better “marker” for the
diagnosis or prognosis of a disease. For example, it has been
experimentally shown in some cases that the disease modules
detected were better predictors of prognosis than any of the
initial individual genes or combinations of them generated
disregarding their network context [74, 75]. It was also shown
that these network modules allow a better stratification of
cancer patients into disease subtypes than the original set of
genes [76].
Another benefit of inferring the network module(s) associ-
ated with a disease is to put that disease into a biological con-
text: since topological modules are also functional modules, it is
possible to associate a given disease with a functional pathway
or a set of pathways (e.g. disease associated to biological pro-
cess/pathway “1” in the example shown in Fig. 4) which could
eventually provide additional information on pathology and
even open new research avenues. This could be particularly im-
portant in the case of rare disorders.
Finally, putting a disease into a network context allows us to
devise network-based strategies for treating it. For example, Lee
et al. [77] detected a malfunctioning network module (signaling
cascade in this case) associated with cancer and designed a
rewiring strategy to generate a pathway with restored activity.
In other cases, even if it was not possible to restore the pathway
by rewiring, the authors managed to engineer a synthetic mod-
ule to perform the function of a malfunctioning one [78].
As commented above, not only diseases are associated to
network clusters but symptoms (patho-phenotypes/clinical
signs) cluster in these networks as well [58]. Consequently, the
same “network propagation” strategies can in principle be used
to “redefine” a set of genes originally associated with a clinical
sign using network information [79]. However, not all clinical
signs cluster in compact modules. Several clinical and biological
factors explain the variable performances of network-based pri-
oritization approaches for clinical sign prediction [80]. These
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variable performances would unevenly impact the results of the
approaches that perform network-based “gene prioritization” of
genes found in a genomic study of undiagnosed patients based
on their clinical signs [81–83].
Other network-based approaches to human
pathologies
Network-based approaches to study human pathologies are not
restricted to the molecular networks described above (networks
representing relationships between molecular entities). Many
other disease-related phenomena have been modeled as net-
works and studied from that point of view. For example, net-
works representing drug-target and drug-drug relationships
(e.g. based on chemical similarity, biological effect similarity,
target(s) similarity, etc.), drug-disease associations, drug side
effects, disease-disease associations or patient-patient relation-
ships have been assembled and studied [84].
The “diseasome” is a network of diseases linked by common
features [35]. Diseases can be linked if they share some
characteristics, such as associated genes [47], microRNAs [85],
functional linkages [86], protein localization [87], protein
interactions [88], comorbidity patterns [89], signs and
Figure 5: Example of network propagation using Cytoscape. Red nodes in the top panel are the initial set. Nodes in the bottom panel are colored according to their rank
in the propagated signal (heat in this case). The network used is the “galFiltered” sample network that comes with Cytoscape’s distributions.
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symptoms [90], or if their associated genes code for sequential
reactions in metabolic pathways [91]. All these formalisms start
from a bipartite graph representation (e.g. gene–disease associa-
tions), and derive a network projection of a single-nodetype
(disease–disease associations). For that, two types of indices are
used (i.e. to associate two diseases based on their own disease–
gene associations): similarity indices and statistic-based indices
(see [92]). These diseasome networks allow us to globally
study relations between diseases from a global/systemic
perspective. Some of these diseasomes are available online so
that interested users can browse these disease connections
(e.g. MalaCards [93], DiseaseConnect [94] and Orphan Disease
Connections (ODCs) [95].
A tripartite network linking phenotypes with patients and
genomic loci has been developed to identify novel genotype–
phenotype relationships [96]. This network has been assembled
from clinical data of thousands of patients with rare disorders
collected by international consortia [97]. Mutations for many of
these patients have been characterized genotypically and their
pathological terms annotated using standard ontologies such as
the Human Phenotype Ontology (HPO) [98].
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